This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / Beyond_Air Nasdaq Listing Extension Granted
Regulatory listing compliance

Beyond_Air Nasdaq Listing Extension Granted

Analysis based on 6 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026

Sentiment
20
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The extension granted by Nasdaq-100 provides q.beyond with crucial time to address its listing compliance, potentially preventing delisting and stabilizing investor confidence. The proposed reverse stock split, if approved, aims to increase q.beyond's stock price, which could positively impact its market valuation and attract investors.

Biotechnology Medical Devices
Event Summary

q.beyond, a medical device and biopharmaceutical company, has received an extension from the Nasdaq-100 Hearings Panel to regain compliance with Nasdaq-100's bid price rule by July 31, 2026. The company's stock has been trading below the minimum bid price requirement. To address this, q.beyond's shareholders will vote on a proposal to authorize a reverse stock split at a special meeting on June 18, 2026. CEO Robert Goodman Jr. expressed confidence in the company's plan to regain compliance while continuing to focus on commercial execution and advancing its nitric oxide platform. q.beyond is also compliant with all other Nasdaq-100 listing requirements. In other recent developments, q.beyond secured a national group purchasing agreement for its inhaled nitric oxide therapy and announced a leadership change with Robert Goodman Jr. becoming CEO. Additionally, its subsidiary Beyond Cancer Limited reported early survival data from a Phase 1 trial for solid tumors, and q.beyond terminated a proposed transaction to sell its NeuroNOS subsidiary to Mapp Biopharmaceutical.

Entities Involved
stock
q.beyond
q.beyond has been granted an extension by the Nasdaq-100 Hearings Panel to regain compliance with the bid price rule, allowing it to maintain its listing on The Nasdaq-100 Stock Market until July 31, 2026. The company plans to propose a reverse stock split to its shareholders to address this issue.
Importance 100.0 Sentiment 30.0
index
Nasdaq-100
Nasdaq-100, through its Hearings Panel, granted q.beyond an extension to comply with its listing rules, demonstrating its role in regulating listed companies and maintaining market standards.
Importance 80.0 Sentiment 0.0
per
Robert Goodman Jr.
As CEO of q.beyond, Robert Goodman Jr. expressed appreciation for the Nasdaq-100 Hearings Panel's decision and affirmed the company's focus on regaining compliance and advancing its commercial execution.
Importance 60.0 Sentiment 20.0
priv
Beyond Cancer Limited
Beyond Cancer Limited, a subsidiary of q.beyond, reported early survival data from a Phase 1 trial for a single injection treatment for solid tumors, indicating ongoing research and development within the broader company structure.
Importance 10.0 Sentiment 0.0
oth
NeuroNOS
The proposed sale of NeuroNOS, a subsidiary of q.beyond, to Mapp Biopharmaceutical was terminated, affecting q.beyond's asset divestment strategy.
Importance 5.0 Sentiment 0.0
priv
Mapp Biopharmaceutical
q.beyond terminated its proposed transaction with Mapp Biopharmaceutical for the sale of its NeuroNOS subsidiary, indicating a change in strategic plans for q.beyond's assets.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.